start-ver=1.4 cd-journal=joma no-vol=127 cd-vols= no-issue=2 article-no= start-page=163 end-page=166 dt-received= dt-revised= dt-accepted= dt-pub-year=2015 dt-pub=20150803 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=The 56th Annual Meeting of the Japanese Society of Pediatric Hematology/Oncology kn-title=‘ζ56‰ρ“ϊ–{¬Ž™ŒŒ‰tE‚ͺ‚ρŠw‰οŠwpW‰ο en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=OdaMegumi en-aut-sei=Oda en-aut-mei=Megumi kn-aut-name=¬“cŽœ kn-aut-sei=¬“c kn-aut-mei=Žœ aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=‰ͺŽR‘εŠw‘εŠw‰@•ΫŒ’ŠwŒ€‹†‰Θ END start-ver=1.4 cd-journal=joma no-vol=68 cd-vols= no-issue=2 article-no= start-page=119 end-page=123 dt-received= dt-revised= dt-accepted= dt-pub-year=2014 dt-pub=201404 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Detection of RBM15-MKL1 Fusion Was Useful for Diagnosis and Monitoring of Minimal Residual Disease in Infant Acute Megakaryoblastic Leukemia en-subtitle= kn-subtitle= en-abstract= kn-abstract=Acute megakaryocytic leukemia (AMKL) with t(1;22)(p13;q13) is a distinct category of myeloid leukemia by WHO classification and mainly reported in infants and young children. Accurate diagnosis of this type of AMKL can be difficult, because a subset of patients have a bone marrow (BM) blast percentage of less than 20% due to BM fibrosis. Therefore, it is possible that past studies have underestimated this type of AMKL. We present here the case of a 4-month-old female AMKL patient who was diagnosed by presence of the RBM15-MKL1 (OTT-MAL) fusion transcript by RT-PCR. In addition, we monitored RBM15-MKL1 fusion at several time points as a marker of minimal residual disease (MRD), and found that it was continuously negative after the first induction chemotherapy even by nested RT-PCR. Detection of the RBM15-MKL1 fusion transcript thus seems to be useful for accurate diagnosis of AMKL with t(1;22)(p13;q13). We recommend that the RBM15-MKL1 fusion transcript be analyzed for all suspected AMKL in infants and young children. Furthermore, monitoring of MRD using this fusion transcript would be useful in treatment of AMKL with t(1;22)(p13;q13). en-copyright= kn-copyright= en-aut-name=TakedaAkiko en-aut-sei=Takeda en-aut-mei=Akiko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=ShimadaAkira en-aut-sei=Shimada en-aut-mei=Akira kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=HamamotoKazuko en-aut-sei=Hamamoto en-aut-mei=Kazuko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=YoshinoSyuuji en-aut-sei=Yoshino en-aut-mei=Syuuji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=NagaiTomoko en-aut-sei=Nagai en-aut-mei=Tomoko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=FujiiYousuke en-aut-sei=Fujii en-aut-mei=Yousuke kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=YamadaMutsuko en-aut-sei=Yamada en-aut-mei=Mutsuko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=NakamuraYoshimi en-aut-sei=Nakamura en-aut-mei=Yoshimi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=WatanabeToshiyuki en-aut-sei=Watanabe en-aut-mei=Toshiyuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=WatanabeYuki en-aut-sei=Watanabe en-aut-mei=Yuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= en-aut-name=YamamotoYuko en-aut-sei=Yamamoto en-aut-mei=Yuko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=11 ORCID= en-aut-name=SakakibaraKanae en-aut-sei=Sakakibara en-aut-mei=Kanae kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=12 ORCID= en-aut-name=OdaMegumi en-aut-sei=Oda en-aut-mei=Megumi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=13 ORCID= en-aut-name=MorishimaTsuneo en-aut-sei=Morishima en-aut-mei=Tsuneo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=14 ORCID= affil-num=1 en-affil= kn-affil=Department of Pediatrics, Okayama University Hospital affil-num=2 en-affil= kn-affil=Department of Pediatrics, Okayama University Hospital affil-num=3 en-affil= kn-affil=Department of Pediatrics, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital affil-num=4 en-affil= kn-affil=Department of Pediatrics, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital affil-num=5 en-affil= kn-affil=Department of Pharmacology, Meijo University affil-num=6 en-affil= kn-affil=Department of Pediatrics, Okayama University Hospital affil-num=7 en-affil= kn-affil=Department of Pediatrics, Okayama University Hospital affil-num=8 en-affil= kn-affil=Department of Division of Medical Support,, Okayama University Hospital affil-num=9 en-affil= kn-affil=Department of Division of Medical Support,, Okayama University Hospital affil-num=10 en-affil= kn-affil=Department of Pediatrics, Okayama University Hospital affil-num=11 en-affil= kn-affil=Department of Pediatrics, Okayama University Hospital affil-num=12 en-affil= kn-affil=Department of Laboratory Medicine, National Hospital Organization Okayama Medical Center affil-num=13 en-affil= kn-affil=Department of Pediatric Hematology/Oncology, Okayama University Hospital affil-num=14 en-affil= kn-affil=Department of Pediatrics, Okayama University Hospital en-keyword=AMKL kn-keyword=AMKL en-keyword=infant kn-keyword=infant en-keyword=RBM15-MKL1 kn-keyword=RBM15-MKL1 en-keyword=OTT-MAL kn-keyword=OTT-MAL END start-ver=1.4 cd-journal=joma no-vol=125 cd-vols= no-issue=1 article-no= start-page=87 end-page=88 dt-received= dt-revised= dt-accepted= dt-pub-year=2013 dt-pub=20130401 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=The 59th Annual Meeting of the Japanese Society of Child Health kn-title=‘ζ59‰ρ“ϊ–{¬Ž™•ΫŒ’‹¦‰οŠwpW‰οŠw‰ο•ρ en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=OdaMegumi en-aut-sei=Oda en-aut-mei=Megumi kn-aut-name=¬“cŽœ kn-aut-sei=¬“c kn-aut-mei=Žœ aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=‰ͺŽR‘εŠw•a‰@@¬Ž™ŒŒ‰tŽξᇉȁC‰ͺŽR‘εŠw‘εŠw‰@•ΫŒ’ŠwŒ€‹†‰Θ END start-ver=1.4 cd-journal=joma no-vol=65 cd-vols= no-issue=2 article-no= start-page=71 end-page=80 dt-received= dt-revised= dt-accepted= dt-pub-year=2011 dt-pub=201104 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Analysis of the Factors That Affect Dental Health Behaviour and Attendance at Scheduled Dental Check-ups Using the PRECEDE-PROCEED Model en-subtitle= kn-subtitle= en-abstract= kn-abstract=A questionnaire survey was administered to 317 parents who attended infant health check-ups in City B, Okayama Prefecture between October, 2008 and March, 2009. The questionnaire survey studied 7 factors based on the PRECEDE-PROCEED Model. We analysed factors that affected oral health behaviour and attendance at scheduled dental health check-ups. The survey containing 22 items concerning matters such as 'QOL' and 'health problems' was posted to parents and guardians in advance, and then collected on the day of the medical check-up. The collected data was analysed using the t-test and Pearson's correlation coefficient, following which we conducted a covariance structure analysis. The results showed that dental health behaviour was directly affected by reinforcing factors, and indirectly associated with enabling and predisposing factors influenced by reinforcing factors. It was also shown that predisposing factors and oral health behaviour were associated with attendance at scheduled oral health check-ups. The results indicated that strengthening oral health education by sharing knowledge that acts as predisposing factors and introducing adaptations of oral health behaviour that that fit individual lives will lead to improved attendance at scheduled dental health check-ups. en-copyright= kn-copyright= en-aut-name=SatoKimiko en-aut-sei=Sato en-aut-mei=Kimiko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=OdaMegumi en-aut-sei=Oda en-aut-mei=Megumi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= affil-num=1 en-affil= kn-affil=Graduate School of Health Sciences, Okayama University affil-num=2 en-affil= kn-affil=Graduate School of Health Sciences, Okayama University en-keyword=PRECEDE-PROCEED model kn-keyword=PRECEDE-PROCEED model en-keyword=dental check-ups kn-keyword=dental check-ups en-keyword=dental health behaviour kn-keyword=dental health behaviour END start-ver=1.4 cd-journal=joma no-vol=41 cd-vols= no-issue=2 article-no= start-page=71 end-page=79 dt-received= dt-revised= dt-accepted= dt-pub-year=1987 dt-pub=198704 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Cell-mediated cytotoxicity-supporting activity of various human gammaglobulin preparations. en-subtitle= kn-subtitle= en-abstract= kn-abstract=

Antibody activity, especially that involved in the reaction of antibody-dependent cell-mediated cytotoxicity (ADCC), of five commercially available human gammaglobulin preparations (standard, pepsin-treated, plasmin-treated, polyethylene glycol-fractionated and S-sulfonated gammaglobulin) was measured. All these gammaglobulin preparations had high titers of hemagglutination inhibition and neutralizing antibody against measles virus. In ADCC reaction, the pepsin-treated gammaglobulin preparation showed no antibody activity. The standard gammaglobulin preparation showed weak activity only when highly diluted. The remaining three preparations showed high activity. Though the S-sulfonated gammaglobulin preparation showed no activity in ADCC reaction, it showed high activity after reconversion by means of oxidation and reduction in vitro. The plasmin-treated gammaglobulin preparation showed greater activity than the polyethylene glycol-fractionated preparation of the optimal concentration. In ADCC tests using the plasmin-treated gammaglobulin preparation, K cell activity was strongly inhibited by Hg (thimerosal), while, in those using the standard gammaglobulin preparation, the activity was hardly influenced by Hg, suggesting that the low ADCC activity of the standard gammaglobulin preparation of high concentrations was due to the inhibitory effect of aggregated immunoglobulin G molecules.

en-copyright= kn-copyright= en-aut-name=WakiguchiHiroshi en-aut-sei=Wakiguchi en-aut-mei=Hiroshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=FujiedaMikiya en-aut-sei=Fujieda en-aut-mei=Mikiya kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=MatsumotoKenji en-aut-sei=Matsumoto en-aut-mei=Kenji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=OharaYuji en-aut-sei=Ohara en-aut-mei=Yuji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=KuroiwaYoshio en-aut-sei=Kuroiwa en-aut-mei=Yoshio kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=WakiguchiAkiko en-aut-sei=Wakiguchi en-aut-mei=Akiko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=ShiraishiTaisuke en-aut-sei=Shiraishi en-aut-mei=Taisuke kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=OdaMegumi en-aut-sei=Oda en-aut-mei=Megumi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=KurashigeTakanobu en-aut-sei=Kurashige en-aut-mei=Takanobu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=KitamuraIsamu en-aut-sei=Kitamura en-aut-mei=Isamu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= affil-num=1 en-affil= kn-affil=Kochi Medical School affil-num=2 en-affil= kn-affil=Kochi Medical School affil-num=3 en-affil= kn-affil=Kochi Medical School affil-num=4 en-affil= kn-affil=Kochi Medical School affil-num=5 en-affil= kn-affil=Kochi Medical School affil-num=6 en-affil= kn-affil=Okayama University affil-num=7 en-affil= kn-affil=Okayama University affil-num=8 en-affil= kn-affil=Okayama University affil-num=9 en-affil= kn-affil=Okayama University affil-num=10 en-affil= kn-affil=Okayama University en-keyword=antibody-dependent cell-mediated cytotoxicity kn-keyword=antibody-dependent cell-mediated cytotoxicity en-keyword=measles kn-keyword=measles en-keyword=immunology kn-keyword=immunology en-keyword=gammaglobulin preparation kn-keyword=gammaglobulin preparation END start-ver=1.4 cd-journal=joma no-vol=43 cd-vols= no-issue=3 article-no= start-page=193 end-page=196 dt-received= dt-revised= dt-accepted= dt-pub-year=1989 dt-pub=198906 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Elevated IgA antibodies to Epstein-Barr virus in children with chronic active Epstein-Barr virus infection. en-subtitle= kn-subtitle= en-abstract= kn-abstract=

Anti-Epstein-Barr virus (EBV) antibodies were tested in 11 children with chronic active EBV infection. Anti-virus capsid antigen (VCA)-IgG antibody titers ranged from 1:640 to 1:10,240. Anti-VCA-IgM antibody was consistently positive in 5 of the 11 patients; anti-VCA-IgA antibody was consistently positive in 6 of the 10 patients; anti-early antigen (EA)-IgG antibody was consistently positive in 10 of the 11 patients and anti-EA-IgA antibody was consistently positive in 4 out of the 7 patients. Anti-EBV nuclear antigen (EBNA) antibody was not detected in two patients. Consistently positive anti-VCA-IgA- and anti-EA-IgA- antibody may be a characteristic feature of abnormal antibody responses in severe chronic active EBV-infection in childhood.

en-copyright= kn-copyright= en-aut-name=WakiguchiHiroshi en-aut-sei=Wakiguchi en-aut-mei=Hiroshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=FujiedaMikiya en-aut-sei=Fujieda en-aut-mei=Mikiya kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=KubotaHaruo en-aut-sei=Kubota en-aut-mei=Haruo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=MatsumotoKenji en-aut-sei=Matsumoto en-aut-mei=Kenji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=WakiguchiAkiko en-aut-sei=Wakiguchi en-aut-mei=Akiko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=KurashigeTakanobu en-aut-sei=Kurashige en-aut-mei=Takanobu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=OdaMegumi en-aut-sei=Oda en-aut-mei=Megumi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= affil-num=1 en-affil= kn-affil=Kochi Medical School affil-num=2 en-affil= kn-affil=Kochi Medical School affil-num=3 en-affil= kn-affil=Kochi Medical School affil-num=4 en-affil= kn-affil=Kochi Medical School affil-num=5 en-affil= kn-affil=Kochi Medical School affil-num=6 en-affil= kn-affil=Kochi Medical School affil-num=7 en-affil= kn-affil=Okayama University en-keyword=IgA antibody kn-keyword=IgA antibody en-keyword=Epstein-Barr virus kn-keyword=Epstein-Barr virus en-keyword=chronic active EBV-infection kn-keyword=chronic active EBV-infection END start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=1990 dt-pub=19900930 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=’Pƒƒwƒ‹ƒyƒXƒEƒCƒ‹ƒXŠ΄υΧ–E‚Ι‘Ξ‚·‚ιVΆŽ™₯“ϋ—cŽ™Šϊ‚̍זE«–Ζ‰u”\‚ΙŠΦ‚·‚ιŒ€‹† en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=¬“cŽœ kn-aut-sei=¬“c kn-aut-mei=Žœ aut-affil-num=1 ORCID= affil-num=1 en-affil= kn-affil=‰ͺŽR‘εŠw END